Investigational drug · Phase 3
Belrestotug
Also called: EOS884448, GSK4428859A
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Cancer, Non-Small Cell, Neoplasms, Head and Neck.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "Belrestotug"
First trial start
2022
Oct 14, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Belrestotug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lung Cancer, Non-Small Cell
- Neoplasms, Head and Neck
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Belrestotug" as an intervention, largest first.
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT05565378 · 351 participants · Start Oct 14, 2022 · Primary completion Oct 26, 2026
Drug: Pembrolizumab; Dostarlimab and 2 more · For: Lung Cancer, Non-Small Cell
Sites: Plantation, Florida; Albuquerque, New Mexico; Chattanooga, Tennessee · 99 sites in all
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06062420 · 316 participants · Start Nov 14, 2023 · Primary completion Sep 10, 2026
Drug: Dostarlimab; Belrestotug and 2 more · For: Neoplasms, Head and Neck
Sites: New Haven, Connecticut; Iowa City, Iowa; St Louis, Missouri · 108 sites in all
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03739710 · 175 participants · Start Jan 24, 2019 · Primary completion May 2, 2024
Drug: Docetaxel; Feladilimab and 4 more · For: Neoplasms
Sites: Los Angeles, California; St Louis, Missouri; The Bronx, New York · 57 sites in all
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsStatus unknown
iTeos Belgium SAIndustry
NCT05060432 · 153 participants · Start Sep 6, 2021 · Primary completion Jul 2024
Drug: EOS-448; pembrolizumab and 3 more · For: Advanced Cancer; Lung Cancer; Head and Neck Cancer and 1 more
Sites: San Diego, California; Bergen, New Jersey; Antwerp, Belgium · 42 sites in all
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT05277051 · 152 participants · Start Mar 22, 2022 · Primary completion Jun 30, 2026
Drug: Remzistotug; Dostarlimab and 3 more · For: Neoplasms
Sites: San Francisco, California; Charlotte, North Carolina; Oklahoma City, Oklahoma · 26 sites in all
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04446351 · 107 participants · Start Jun 25, 2020 · Primary completion Dec 31, 2026
Drug: GSK6097608; Dostarlimab and 2 more · For: Neoplasms
Sites: Los Angeles, California; Boston, Massachusetts; Dallas, Texas · 11 sites in all
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06472076 · 88 participants · Start Jun 10, 2024 · Primary completion Jun 30, 2026
Drug: Dostarlimab; Belrestotug and 2 more · For: Lung Cancer, Non-Small Cell
Sites: Ocala, Florida; Honolulu, Hawaii; Lexington, Kentucky · 108 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06926673 · 62 participants · Start Dec 23, 2021 · Primary completion May 2, 2024
Drug: Dostarlimab; Belrestotug. and 1 more · For: Neoplasms
Sites: Nashville, Tennessee; Edmonton, Canada; Brampton, Canada · 15 sites in all
iTeos TherapeuticsIndustry
NCT05289492 · 16 participants · Start May 1, 2022 · Primary completion Nov 29, 2023
Drug: EOS884448; Iberdomide and 1 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Norwich, Connecticut; Hackensack, New Jersey · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase I First-Time-in-Human, Open-label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.
Siu LL, Hamid O, Schneider R, et al. · Clin Cancer Res 2026
- ENTRÉE Lung: An Open-label Platform Study Investigating the Safety and Pharmacokinetics of Belrestotug Combinations in Advanced Non-Small Cell Lung Cancer.
Spigel DR, Lo Russo G, Cousin S, et al. · Clin Cancer Res 2026
Also in development for Lung Cancer, Non-Small Cell
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- NelistotugGSK6097608Phase 22 trials
GSK · Lung Cancer, Non-Small Cell, Neoplasms, Head and Neck
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.